Trial Profile

Phase III, Open Label Randomized Comparative Clinical Trial of Oral Posaconazole Three Times Per Day versus Weekly High Dose Amphotericin B Lipid Complex (ABLC) for The Prevention of Invasive Fungal Infections In Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Sep 2019 Results published in the Antimicrobial Agents and Chemotherapy.
21 Nov 2009 Status changed from recruiting to active, no longer recruiting ,as reported by M.D. Anderson Cancer Center record.
15 Apr 2009 Enzon Pharmaceuticals added as trial sponsor and lead trial centre as reported by M.D. Anderson Cancer Center.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com